Johnson & Johnson (NYSE:JNJ) is Lowe Brockenbrough & Co. Inc.’s 10th Largest Position

Lowe Brockenbrough & Co. Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 107,144 shares of the company’s stock after selling 2,868 shares during the period. Johnson & Johnson accounts for about 1.7% of Lowe Brockenbrough & Co. Inc.’s investment portfolio, making the stock its 10th biggest holding. Lowe Brockenbrough & Co. Inc.’s holdings in Johnson & Johnson were worth $17,503,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. RKL Wealth Management LLC grew its stake in shares of Johnson & Johnson by 2.1% in the second quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock worth $8,562,000 after acquiring an additional 1,010 shares during the period. Geller Advisors LLC grew its stake in shares of Johnson & Johnson by 7.5% in the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after acquiring an additional 648 shares during the period. Simon Quick Advisors LLC grew its stake in shares of Johnson & Johnson by 296.9% in the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after acquiring an additional 6,537 shares during the period. Lokken Investment Group LLC grew its stake in shares of Johnson & Johnson by 1.6% in the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after acquiring an additional 201 shares during the period. Finally, Keebeck Alpha LP grew its position in Johnson & Johnson by 13.4% during the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock valued at $788,000 after buying an additional 525 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Raymond James cut their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. SVB Leerink cut their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Atlantic Securities cut their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Price Performance

JNJ stock opened at $168.74 on Monday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company’s fifty day moving average price is $176.14 and its 200-day moving average price is $171.20. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The company has a market capitalization of $441.17 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 3.19 and a beta of 0.56.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Insider Transactions at Johnson & Johnson

In other news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 233,611 shares of company stock valued at $40,960,735. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.